Skip to main content
BDX logo

BDX · Becton Dickinson & Co · Financials

Track BDX — free
$198.91 -1.51 (-0.75%)
Market Cap
$54.16B
Shares
272.39M
Volume · Oct 23 1.3M Avg daily vol (3M) 1.74M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Revenue
$21.84B +8.2%
FY2025 Revenue FY2007–FY2025
Net Income
$1.68B -1.6%
FY2025 Net Income FY2007–FY2025
Gross Margin
45.44% +0.2pp
FY2025 Gross Margin FY2007–FY2025
Operating Margin
11.81% -0.1pp
FY2025 Operating Margin FY2007–FY2025
Diluted EPS
$4.58 -0.7%
FY2025 Diluted EPS FY2007–FY2025
Operating Cash Flow
$3.43B -10.8%
FY2025 Operating Cash Flow FY2007–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item FY2026 (G) TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010 FY2009 FY2008 FY2007
— $22.42B $21.84BG $20.18BG $19.37BG $18.87BG $19.13B $16.07B $17.29B $15.98B $12.09B $12.48B $10.28B $8.45B $8.05B $7.71B $7.58B $7.12B $6.99B $6.9B $6.28B
— $11.94B $11.92B $11.05B $11.2B $10.39B $10.5B $9.28B $9B $8.71B $6.13B $6.49B $5.59B $4.15B $3.88B $3.76B $3.63B $3.43B $3.31B $3.36B $3.03B
— $10.47B $9.93Bd $9.13Bd $8.17Bd $8.48Bd $8.63Bd $7.58B $8.29B $7.27B $5.94B $5.99B $4.7B $4.3B $4.17Bd $3.95Bd $3.96Bd $3.7Bd $3.68Bd $3.54Bd $3.25Bd
— — 45.44%d 45.22%d 42.17%d 44.92%d 45.12%d 47.14% 47.94% 45.48% 49.14% 47.99% 45.66% 50.92% 51.79%d 51.28%d 52.2%d 51.88%d 52.6%d 51.33%d 51.73%d
— $1.27B $1.27B $1.19B $1.24B $1.26B $1.28B $1.04B $1.06B $1B $770M $828M $632M $550M $494M $472M $470M $422.77M $404.57M — —
— $5.55B $5.28B $4.86B $4.72B $4.71B $4.72B $4.19B $4.33B $4.02B $2.91B $3.01B $2.56B $2.15B $2.42B $1.92B $1.82B $1.69B $1.68B $1.67B $1.58B
— $1.56B $1.59B $1.47B $1.47B $1.43B $1.4B $1.38B $1.5B $1.26B $553M $552M $346M $84M $83M $71M $54M $46.96M — — —
— $2.45B $2.46B $2.29B $2.29B $2.23B $2.23B $2.12B $2.25B $1.98B $1.09B $1.11B $891M $562M $546M $511M $494M $491.42M $464.6M $471.96M $441.1M
— $693M $275M $387M $239M $123M $44M $84M — — $85M $526M $271M — — — — — — — —
— $20.1B $19.26B $17.78B $17.26B $16.59B $16.88B $15.16B $15.53B $14.47B $10.57B $11.05B $9.21B $6.84B $6.8B $6.15B $5.92B $5.54B $5.4B $5.41B $5.1B
— $2.31B $2.58B $2.4B $2.11B $2.28B $2.25B $912M $1.76B $1.51B $1.52B $1.43B $1.07B $1.61B $1.25B $1.56B $1.67B $1.58B $1.59B $1.49B $1.18B
— — 11.81% 11.88% 10.9% 12.09% 11.76% 5.67% 10.18% 9.44% 12.59% 11.46% 10.45% 19.01% 15.57% 20.21% 21.97% 22.21% 22.75% 21.57% 18.86%
— $4.77B $5.04B $4.68B $4.4B $4.51B $4.48B $3.03B $4.01B $3.49B $2.61B $2.54B $1.97B $2.17B $1.8B $2.07B $2.16B $2.07B $2.05B $1.96B $1.63B
— $590M $613M $528M $452M $398M $469M $528M $639M $706M $521M $388M $371M $135M $138M $135M $84M $51.26M $40.39M $36.34M $46.42M
— $23M $38M $163M $49M $16M $9M $7M $12M $65M $76M $21M $15M $46M $40M $50M $43M — — — —
— $46M -$123M -$28M -$46M -$117M -$99M $23M $43M $305M -$101M $11M $21M $5M $9M -$1M -$7M $497K -$3.85M -$1.48M $944K
— — — — — — — $13M $18M $8M $3M $8M $9M $13M $5M $12M $3M $4.85M $4.54M $4.64M —
— $1.79B $1.88B $2.01B $1.66B $1.78B $1.69B $414M $1.18B $1.17B $976M $1.07B $739M $1.52B $1.17B $1.47B $1.62B $1.57B $1.58B $1.49B $1.19B
— $228M $203M $300M $132M $148M $88M $62M -$57M $862M -$124M $97M $44M $337M $236M $363M $417M $451.9M $411.25M $411.93M $343.89M
— $941M $1.68B $1.71B $1.48B $1.78B $2.09B $874M $1.23B $311M $1.1B $976M $695M $1.19B $1.29B $1.17B $1.27B $1.32B $1.23B $1.13B $890.03M
— — 7.68% 8.45% 7.66% 9.43% 10.94% 5.44% 7.13% 1.95% 9.1% 7.82% 6.76% 14.03% 16.05% 15.18% 16.76% 18.49% 17.63% 16.34% 14.17%
— — $1.68B $1.71B $1.42B $1.69B $2B $767M $1.08B $159M $1.03B $976M $695M — — — — — — — —
— $1.11B $1.52B $1.52B $1.42B $2.38B $2.55B $609M $859M $125M $1.31B $786M -$42M $699M $1.58B $1.04B $1.06B $1.23B $936.45M $1.05B $1.13B
USD/shares — $2.00 $4.58 $4.62 $3.91 $4.66 $5.44 $2.16 $3.15 $0.49 $3.69 $3.61 $2.70 $4.82 $5.21 $4.47 $4.52 $4.42 $4.03 $3.62 $2.85
USD/shares $12.62 – $12.72* $2.00 $4.58G $4.61G $3.88G $4.62G $5.39G $2.13G $3.10 $0.47 $3.62 $3.53 $2.63 $4.71 $5.10 $4.39 $4.42 $4.32 $3.92 $3.51 $2.74
shares — — 365.89M 368.58M 364.15M 362.53M 367.97M 354.85M 343.37M 328.63M 278.5M 270.56M 257.63M 245.88M 248.24M 261.35M 281.33M 298.07M 305.89M 310.78M —
shares — — 366.98M 370.16M 366.83M 365.53M 371.54M 359.22M 349.51M 336.6M 284.4M 276.71M 263.95M 251.49M 253.37M 266.08M 287.83M 305.45M 313.93M 321.41M —
d Gross profit for periods the company did not report it, or tagged its operating income as gross profit, is Revenue − Cost of Revenue. Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $10.02B in buybacks, $12.92B in dividends.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current debt and lease obligations 2026-06-30 USD 3,297,000,000 10-Q filed 2026-08-06
Noncurrent debt carrying amount 2026-06-30 USD 13,511,000,000 10-Q filed 2026-08-06
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
1 filing has incomplete source or extraction coverage. Verified observations are shown; missing observations do not establish that debt was unchanged.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

3.855% Notes due 2033

Note · Becton Dickinson Euro Finance S.à r.l.

Reference: 3.855% Notes due 2033

Active
Original principal
EUR 600,000,000
Outstanding
—
Commitment
—
Availability
—
Maturity
—

Last reported interest terms: 3.855% Reported 2026-05-20 Later filings may not restate these terms; this does not confirm they still apply.

Covenant terms for this agreement are not yet verified.

Documents and filing history
  1. Issuance · 2026-05-20 Original principal EUR 600,000,000 Exact source document Parent 8-K filing · 2026-05-20
    On May 20, 2026, Becton Dickinson Euro Finance S.à r.l., a private limited liability company (société à responsabilité limitée) incorporated under the laws of the Grand Duchy of Luxembourg ("Becton Finance") and an indirect, wholly-owned subsidiary of Becton, Dickinson and Company ("BD"), issued €600,000,000 aggregate principal amount of its 3.855% Notes due 2033 (the "Becton Finance Notes") in an underwritten public offering.
    Issuer evidence: On May 20, 2026, Becton Dickinson Euro Finance S.à r.l., a private limited liability company (société à responsabilité limitée) incorporated under the laws of the Grand Duchy of Luxembourg ("Becton Finance") and an indirect, wholly-owned subsidiary of Becton, Dickinson and Company ("BD"), issued €600,000,000 aggregate principal amount of its 3.855% Notes due 2033 (the "Becton Finance Notes") in an underwritten public offering.
    Supporting evidence: On May 20, 2026, Becton Dickinson Euro Finance S.à r.l., a private limited liability company (société à responsabilité limitée) incorporated under the laws of the Grand Duchy of Luxembourg ("Becton Finance") and an indirect, wholly-owned subsidiary of Becton, Dickinson and Company ("BD"), issued €600,000,000 aggregate principal amount of its 3.855% Notes due 2033 (the "Becton Finance Notes") in an underwritten public offering.
    Supporting evidence: On May 20, 2026, Becton Dickinson Euro Finance S.à r.l., a private limited liability company (société à responsabilité limitée) incorporated under the laws of the Grand Duchy of Luxembourg ("Becton Finance") and an indirect, wholly-owned subsidiary of Becton, Dickinson and Company ("BD"), issued €600,000,000 aggregate principal amount of its 3.855% Notes due 2033 (the "Becton Finance Notes") in an underwritten public offering.
  2. Issuance · 2026-05-11 Original principal EUR 600,000,000 Exact source document Parent 8-K filing · 2026-05-12
    On May 11, 2026, Becton, Dickinson and Company (“BD”), together with its indirect, wholly-owned subsidiary, Becton Dickinson Euro Finance S.à r.l., a private limited liability company (société à responsabilité limitée) incorporated under the laws of the Grand Duchy of Luxembourg (“Becton Finance”), entered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Bank PLC, BNP PARIBAS, Goldman Sachs & Co. LLC and Morgan Stanley & Co. International plc and the several other underwriters named therein (the “Underwriters”) in connection with the offer and sale by Becton Finance to the Underwriters (the “Offering”) of €600,000,000 aggregate principal amount of its 3.855% Notes due 2033 (the “Euro Notes”). The Euro Notes will be fully and unconditionally guaranteed on a senior unsecured basis by BD.
    Issuer evidence: On May 11, 2026, Becton, Dickinson and Company (“BD”), together with its indirect, wholly-owned subsidiary, Becton Dickinson Euro Finance S.à r.l., a private limited liability company (société à responsabilité limitée) incorporated under the laws of the Grand Duchy of Luxembourg (“Becton Finance”), entered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Bank PLC, BNP PARIBAS, Goldman Sachs & Co. LLC and Morgan Stanley & Co. International plc and the several other underwriters named therein (the “Underwriters”) in connection with the offer and sale by Becton Finance to the Underwriters (the “Offering”) of €600,000,000 aggregate principal amount of its 3.855% Notes due 2033 (the “Euro Notes”). The Euro Notes will be fully and unconditionally guaranteed on a senior unsecured basis by BD.
    Supporting evidence: On May 11, 2026, Becton, Dickinson and Company (“BD”), together with its indirect, wholly-owned subsidiary, Becton Dickinson Euro Finance S.à r.l., a private limited liability company (société à responsabilité limitée) incorporated under the laws of the Grand Duchy of Luxembourg (“Becton Finance”), entered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Bank PLC, BNP PARIBAS, Goldman Sachs & Co. LLC and Morgan Stanley & Co. International plc and the several other underwriters named therein (the “Underwriters”) in connection with the offer and sale by Becton Finance to the Underwriters (the “Offering”) of €600,000,000 aggregate principal amount of its 3.855% Notes due 2033 (the “Euro Notes”). The Euro Notes will be fully and unconditionally guaranteed on a senior unsecured basis by BD.
    Supporting evidence: On May 11, 2026, Becton, Dickinson and Company (“BD”), together with its indirect, wholly-owned subsidiary, Becton Dickinson Euro Finance S.à r.l., a private limited liability company (société à responsabilité limitée) incorporated under the laws of the Grand Duchy of Luxembourg (“Becton Finance”), entered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Bank PLC, BNP PARIBAS, Goldman Sachs & Co. LLC and Morgan Stanley & Co. International plc and the several other underwriters named therein (the “Underwriters”) in connection with the offer and sale by Becton Finance to the Underwriters (the “Offering”) of €600,000,000 aggregate principal amount of its 3.855% Notes due 2033 (the “Euro Notes”). The Euro Notes will be fully and unconditionally guaranteed on a senior unsecured basis by BD.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
3.13×
Peer median 2.38×
EV/EBIT
30.39×
Peer median 29.28×
P/E (TTM)
—
Peer median 25.54×

Peer medians compare against the 14 similar-size Medical Instruments & Supplies companies (of 51 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Medical $11,456,000,000 $10,074,000,000 $9,502,000,000 $8,841,000,000 $8,361,000,000 $7,637,000,000 $9,064,000,000 $8,616,000,000
Interventional $5,217,000,000 $4,980,000,000 $4,736,000,000 $4,464,000,000 $4,239,000,000 $3,762,000,000 $3,926,000,000 $3,037,000,000
Life Sciences $5,167,000,000 $5,191,000,000 $5,133,000,000 $5,564,000,000 $6,530,000,000 $4,675,000,000 $4,300,000,000 $4,330,000,000

By Geography (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
United States $12,790,000,000 $11,663,000,000 $11,113,000,000 $10,722,000,000 $10,371,000,000 $9,161,000,000 $9,730,000,000 $8,768,000,000
Non Us $9,049,000,000 $8,515,000,000 $8,258,000,000 $8,148,000,000 $8,760,000,000 $6,912,000,000 $7,560,000,000 $7,215,000,000
EMEA $4,729,000,000 $4,402,000,000 $4,244,000,000 $4,043,000,000 $4,548,000,000 $3,734,000,000 $3,837,000,000 —
Asia $3,093,000,000 $2,906,000,000 $2,913,000,000 $3,047,000,000 $3,069,000,000 $2,384,000,000 $2,726,000,000 $2,460,000,000
Others Country $1,227,000,000 $1,207,000,000 $1,102,000,000 $1,058,000,000 $1,142,000,000 $794,000,000 $997,000,000 $1,457,000,000
Middle East and Africa — — — — — $448,000,000 $478,000,000 —
Europe — — — — — $3,480,000,000 $3,359,000,000 $3,298,000,000

By Product & Service (USD)

Component FY2019 FY2018
Interventional Specialties Brachytherapyand Feeding Products $185,000,000 $194,000,000
IV Fluids $11,000,000 $17,000,000

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component FY2025 FY2024 FY2023
Medical $4,140,000,000 $3,583,000,000 $3,352,000,000
Interventional $2,253,000,000 $2,115,000,000 $1,939,000,000
Life Sciences $1,641,000,000 $1,616,000,000 $1,599,000,000

Operating Margin by Segment (%)

Component FY2025 FY2024 FY2023
Medical 36.1% 35.6% 35.3%
Interventional 43.2% 42.5% 40.9%
Life Sciences 31.8% 31.1% 31.2%
Key facts CIK 10795 CUSIP 075887109 13F (30d) 384 filings 359 filers Visit website Investor relations